What happened
FDA announced the availability of final industry guidance titled “Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers.” The question-and-answer guidance addresses commonly asked questions from applicants and other interested parties about postapproval manufacturing changes to biosimilar and interchangeable biosimilar products licensed under the Public Health Service Act. It finalizes the draft guidance with the same title issued on July 23, 2024. The guidance was issued by FDA’s Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research under docket FDA-2024-D-2581. The source identifies it as Final Level 1 Guidance.
Why it matters
For pharmaceutical and biologics manufacturers, the guidance may be relevant when planning or managing manufacturing changes after approval of a licensed biosimilar or interchangeable biosimilar. Its question-and-answer format may help applicants identify FDA’s responses to common postapproval manufacturing-change questions. Because the source excerpt does not include the individual questions, answers, or reporting expectations, specific GMP actions or requirements cannot be inferred from this notice alone.
Key topics: postapproval manufacturing changes, biosimilar and interchangeable biosimilar products, final question-and-answer guidance